These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 30531473)

  • 1. Gadolinium-based contrast agents: why nephrologists need to be concerned.
    Leyba K; Wagner B
    Curr Opin Nephrol Hypertens; 2019 Mar; 28(2):154-162. PubMed ID: 30531473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents.
    Kitajima K; Maeda T; Watanabe S; Ueno Y; Sugimura K
    Int J Urol; 2012 Sep; 19(9):806-11. PubMed ID: 22571387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadolinium-associated nephrogenic systemic fibrosis.
    Schlaudecker JD; Bernheisel CR
    Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Nephrogenic systemic fibrosis: a severe complication of use to gadolinium in patients with kidney failure].
    Mundim JS; Lorena Sde C; Abensur H; Elias RM; Moysés RM; Castro MC; Romão Júnior JE
    Rev Assoc Med Bras (1992); 2009; 55(2):220-5. PubMed ID: 19488662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gadolinium-associated nephrogenic systemic fibrosis in patients with renal failure: the need for an interdisciplinary helping network.
    Stratta P; Canavese C; Quaglia M; Fenoglio R
    Rheumatology (Oxford); 2010 Apr; 49(4):821-3. PubMed ID: 20032228
    [No Abstract]   [Full Text] [Related]  

  • 6. Renal function, nephrogenic systemic fibrosis and other adverse reactions associated with gadolinium-based contrast media.
    Canga A; Kislikova M; Martínez-Gálvez M; Arias M; Fraga-Rivas P; Poyatos C; de Francisco AL
    Nefrologia; 2014; 34(4):428-38. PubMed ID: 25036056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrogenic systemic fibrosis.
    Weinreb JC; Kuo PH
    Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadolinium-Based Contrast Agents: Updates and Answers to Typical Questions Regarding Gadolinium Use.
    Cheong BYC; Wilson JM; Preventza OA; Muthupillai R
    Tex Heart Inst J; 2022 May; 49(3):. PubMed ID: 35612906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gadolinium-based contrast agents in children.
    Rozenfeld MN; Podberesky DJ
    Pediatr Radiol; 2018 Aug; 48(9):1188-1196. PubMed ID: 30078039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary applications and limitations of magnetic resonance imaging contrast materials.
    Natalin RA; Prince MR; Grossman ME; Silvers D; Landman J
    J Urol; 2010 Jan; 183(1):27-33. PubMed ID: 19913804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure.
    Bernstein EJ; Schmidt-Lauber C; Kay J
    Best Pract Res Clin Rheumatol; 2012 Aug; 26(4):489-503. PubMed ID: 23040363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrogenic systemic fibrosis and gadolinium-containing radiological contrast agents: an update.
    Jalandhara N; Arora R; Batuman V
    Clin Pharmacol Ther; 2011 Jun; 89(6):920-3. PubMed ID: 21471962
    [No Abstract]   [Full Text] [Related]  

  • 13. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
    Weinreb JC; Abu-Alfa AK
    J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is it safe to use gadolinium-based contrast agents in MRI?
    Pullicino R; Das K
    J R Coll Physicians Edinb; 2017 Sep; 47(3):243-246. PubMed ID: 29465099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Causal relationship between the use of gadolinium based contrast media and nephrogenic systemic fibrosis].
    Varela CU; Prieto-Rayo JC
    Rev Med Chil; 2014 Dec; 142(12):1565-74. PubMed ID: 25693439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
    Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
    Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gadolinium and nephrogenic systemic fibrosis: association or causation.
    Kurtkoti J; Snow T; Hiremagalur B
    Nephrology (Carlton); 2008 Jun; 13(3):235-41. PubMed ID: 18221255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging.
    Chrysochou C; Power A; Shurrab AE; Husain S; Moser S; Lay J; Salama AD; Kalra PA
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):484-9. PubMed ID: 20093350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free gadolinium is a likely trigger of nephrogenic systemic fibrosis.
    Abraham JL; Edward M
    AJR Am J Roentgenol; 2009 Oct; 193(4):W354; author reply W355. PubMed ID: 19770307
    [No Abstract]   [Full Text] [Related]  

  • 20. GBCAs and Risk for Nephrogenic Systemic Fibrosis: A Literature Review.
    Beam AS; Moore KG; Gillis SN; Ford KF; Gray T; Steinwinder AH; Graham A
    Radiol Technol; 2017 Jul; 88(6):583-589. PubMed ID: 28900045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.